1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:
All Non-Small Cell Lung Cancer (NSCLC) patients
Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)
2. Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Nintedanib + docetaxel
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin
Gemcitabine mono or in combination with carboplatin / cisplatin
Atezolizumab (Tecentriq)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
Paclitaxel mono or in combination with carboplatin / cisplatin
Doxetaxel mono or in combination with carboplatin / cisplatin
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin
3. If your trust does not treat Stage IIIB/IV NSCLC patients and you refer your patients to another trust, please state to which trust patients are referred

Download response Non-small Cell Lung Cancer. 301117